The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 09, 2016
Filed:
Jul. 11, 2014
Applicant:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Inventor:
Li Zhang, Baldwin Place, NY (US);
Assignee:
Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 16/22 (2006.01); C07K 19/00 (2006.01); C07K 16/32 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); C07K 16/22 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract
The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist.